RS Camplejohn

1.4k total citations
27 papers, 1.2k citations indexed

About

RS Camplejohn is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, RS Camplejohn has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 10 papers in Cancer Research. Recurrent topics in RS Camplejohn's work include Cancer Genomics and Diagnostics (9 papers), Cancer-related Molecular Pathways (6 papers) and HER2/EGFR in Cancer Research (4 papers). RS Camplejohn is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Cancer-related Molecular Pathways (6 papers) and HER2/EGFR in Cancer Research (4 papers). RS Camplejohn collaborates with scholars based in United Kingdom, Canada and Thailand. RS Camplejohn's co-authors include R. A. Walker, DM Barnes, D M Barnes, R R Millis, Jiřina Bártková, MA Richards, Steven M. Picksley, Martine E. Lomax, Julia A. Newton and M A Richards and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and British Journal of Cancer.

In The Last Decade

RS Camplejohn

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
RS Camplejohn United Kingdom 18 716 425 417 255 202 27 1.2k
P Bertheau France 16 800 1.1× 536 1.3× 456 1.1× 252 1.0× 287 1.4× 35 1.5k
Bonnie L. King United States 19 605 0.8× 465 1.1× 361 0.9× 206 0.8× 145 0.7× 36 1.2k
L Andrac France 25 661 0.9× 659 1.6× 370 0.9× 258 1.0× 144 0.7× 75 1.5k
Robert B. Jenkins United States 5 734 1.0× 215 0.5× 440 1.1× 150 0.6× 325 1.6× 8 1.1k
Kay Friedrichs Germany 16 674 0.9× 521 1.2× 479 1.1× 154 0.6× 88 0.4× 34 1.4k
Rafael Molina Spain 18 1.1k 1.5× 557 1.3× 473 1.1× 186 0.7× 476 2.4× 33 1.7k
Holger Dieterich Switzerland 11 793 1.1× 736 1.7× 579 1.4× 207 0.8× 158 0.8× 14 1.6k
Jan Mattsson Sweden 20 844 1.2× 299 0.7× 419 1.0× 209 0.8× 95 0.5× 43 1.4k
Regan Fulton United States 17 664 0.9× 250 0.6× 371 0.9× 137 0.5× 166 0.8× 31 1.1k
M Giai Italy 18 460 0.6× 474 1.1× 268 0.6× 106 0.4× 118 0.6× 33 1.2k

Countries citing papers authored by RS Camplejohn

Since Specialization
Citations

This map shows the geographic impact of RS Camplejohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RS Camplejohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RS Camplejohn more than expected).

Fields of papers citing papers by RS Camplejohn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RS Camplejohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RS Camplejohn. The network helps show where RS Camplejohn may publish in the future.

Co-authorship network of co-authors of RS Camplejohn

This figure shows the co-authorship network connecting the top 25 collaborators of RS Camplejohn. A scholar is included among the top collaborators of RS Camplejohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RS Camplejohn. RS Camplejohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nutting, Chris, RS Camplejohn, R Gilchrist, et al.. (2000). A Patient with 17 Primary Tumours and a Germ Line Mutation in : Tumour Induction by Adjuvant Therapy?. Clinical Oncology. 12(5). 300–304. 31 indexed citations
2.
Varley, J M, Peter Chapman, Gail McGown, et al.. (1998). Genetic and functional studies of a germline TP53 splicing mutation in a Li–Fraumeni-like family. Oncogene. 16(25). 3291–3298. 41 indexed citations
3.
Lomax, Martine E., D M Barnes, Ted R. Hupp, Steven M. Picksley, & RS Camplejohn. (1998). Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members. Oncogene. 17(5). 643–649. 88 indexed citations
4.
Lomax, Martine E., D M Barnes, R Gilchrist, et al.. (1997). Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene. 14(15). 1869–1874. 54 indexed citations
5.
Thomas, H., et al.. (1996). An inbred colony of oncogene transgenic mice: diversity of tumours and potential as a therapeutic model. British Journal of Cancer. 73(1). 65–72. 7 indexed citations
6.
Camplejohn, RS, J. Jefferson P. Perry, SV Hodgson, et al.. (1995). A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. British Journal of Cancer. 72(3). 654–662. 32 indexed citations
7.
Camplejohn, RS, C. M. Ash, C E Gillett, et al.. (1995). The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. British Journal of Cancer. 71(1). 140–145. 50 indexed citations
8.
Camplejohn, RS. (1994). The measurement of intracellular antigens and DNA by multiparametric flow cytometry. Journal of Microscopy. 176(1). 1–7. 17 indexed citations
9.
Hands, L, et al.. (1993). Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study. British Journal of Cancer. 67(5). 1145–1153. 44 indexed citations
10.
11.
Barnes, DM, et al.. (1991). The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. British Journal of Cancer. 63(3). 444–446. 120 indexed citations
12.
Yu, C. C.‐W., Peter A. Hall, Christopher D.�M. Fletcher, et al.. (1991). Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology. 19(1). 29–34. 133 indexed citations
13.
Camplejohn, RS, et al.. (1990). DNA index, S-phase fraction, histological grade and prognosis in breast cancer. British Journal of Cancer. 61(5). 671–674. 99 indexed citations
14.
O'Reilly, S.M., RS Camplejohn, D M Barnes, et al.. (1990). Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.. Journal of Clinical Oncology. 8(12). 2040–2046. 99 indexed citations
15.
McLelland, Janet, Julia A. Newton, Marian Malone, RS Camplejohn, & Anthony C. Chu. (1989). A flow cytometric study of Langerhans cell histiocytosis. British Journal of Dermatology. 120(4). 485–491. 41 indexed citations
16.
Camplejohn, RS, et al.. (1988). The flow cytometry of melanocytic skin lesions. British Journal of Cancer. 58(5). 606–609. 31 indexed citations
17.
Walker, R. A. & RS Camplejohn. (1988). Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. British Journal of Cancer. 57(3). 281–283. 102 indexed citations
18.
Newton, Julia A., et al.. (1987). A flow cytometric study of the significance of DNA aneuploidy in cutaneous lesions. British Journal of Dermatology. 117(2). 169–174. 29 indexed citations
19.
Guthrie, David, et al.. (1986). Screening tests for Sezary cells in cutaneous T-cell lymphomas. Clinical & Laboratory Haematology. 8(2). 109–114. 3 indexed citations
20.
Britton, D C, G Boné, Nicholas A. Wright, & RS Camplejohn. (1975). Measurement of cell production rates in human gastro-intestinal cancer-a guide to treatment?. British journal of surgery. 62(10). 813–815. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P Bertheau Breakdown of academic impact, for papers by Bonnie L. King Breakdown of academic impact, for papers by L Andrac Breakdown of academic impact, for papers by Robert B. Jenkins Breakdown of academic impact, for papers by Kay Friedrichs Breakdown of academic impact, for papers by Rafael Molina Breakdown of academic impact, for papers by Holger Dieterich Breakdown of academic impact, for papers by Jan Mattsson Breakdown of academic impact, for papers by Regan Fulton Breakdown of academic impact, for papers by M Giai
Rankless by CCL
2026